Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer

NCT03193060 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03193060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03193060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
September 19, 2017
Completion date
December 27, 2019
Enrollment
308 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

localized or locally advanced prostate cancer